The Clinical Studies
Unit of Boston University
Psychiatry

Boston University Medical Campus
Suite 1150, Doctors Office Building
Boston | 617.414.1990

720 Harrison Ave
Crown Colony Executive Office Park
300 Congress St., Suite 401
Quincy | 617.414.1990
The Clinical Studies Unit of Boston University Psychiatry Associates, Inc is directed by Domenic A. Ciraulo M.D., Professor and Chairman, Department of Psychiatry at Boston University Medical School and Psychiatrist-in-Chief at Boston Medical Center. He is board certified by the American Board of Psychiatry and Neurology with added qualifications in addiction psychiatry. He is a distinguished fellow of the American Psychiatry Association and has served on its council on addictions. Dr. Ciraulo is a member of the American Medical Association, the Massachusetts Medical Society, the Massachusetts Psychiatric Society, and the Research Society on Alcoholism. He has been listed in Best Doctors since 1992, named by the Consumer Research Council of America as one of "America's Top Psychiatrists," and by Town and Country Magazine as a "Best Medical Specialist" in North America. He serves as study chair for the National Institute on Alcohol Abuse and Alcoholism's National Clinical Investigation Group for medication studies in alcoholism. His research is highly regarded and published in leading medical journals, including the Journal of the American Medical Association (JAMA). He is the editor of several medical textbooks, including Clinical Manual of Chemical Dependence, Clinical Manual of Addiction Psychopharmacology, Pharmacotherapy of Depression, and Drug Interactions in Psychiatry. In addition to his research publications and monographs, he has contributed over 50 chapters to textbooks in the field.

Under his leadership, the Clinical Studies Unit has specialized in developing novel therapies for alcoholism, stimulant dependence, and prescription drug abuse. Current research interests of the CSU include medications that reduce the desire to drink alcohol; the use of transcranial magnetic stimulation for the treatment of depression, alcoholism and addiction; and the use of genetic markers and brain imaging to discover factors that contribute to successful treatment.